U.S. investors, Big Pharma race to find new medicines in China
Publishing timestamp: 2025-02-13 12:27:17
Summary
U.S. investors and large pharmaceutical companies are increasingly looking for new medicines in China, with almost 30% of Big Pharma deals involving Chinese companies. This trend is driven by the quality and quantity of assets being developed in China, as well as the lower costs of early studies. While some see this as an opportunity to bring down drug prices, others worry about the impact on U.S. biotech companies if large pharmaceutical companies start acquiring assets from China instead of American startups. There is also a potential risk of intervention from policymakers to stop these deals.
Sentiment: MIXED
Tickers: MRK, GILD, SMMT, VKTX,
Keywords: united states, gilead sciences inc, health care industry, viking therapeutics inc, china, donald j. trump, business news, merck & co inc, summit therapeutics inc, jiangsu hengrui medicine co ltd,
Source: https://www.cnbc.com/2025/02/13/china-biopharma-deals-rise-with-summit-merck.html